Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice

Diabetes, Obesity and Metabolism

Volumn 16, Issue 12, 2014, Pages 1214-1222

  O'Harte, F P M ^a   Franklin, Z J ^a   Irwin, N ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Acylated peptide analogues; Animal models of diabetes; Chronic effects of peptide antagonists; Glucagon receptor antagonist; Glucose tolerance

Indexed keywords

ANTIDIABETIC AGENT; CARBON DIOXIDE; CHOLESTEROL; GLUCAGON; GLUCAGON RECEPTOR; GLUCAGON RECEPTOR PEPTIDE ANTAGONIST; INSULIN; PEPTIDE; UNCLASSIFIED DRUG; GLUCAGON, DESHISTIDYL(1)-PROLYL(4)-GLUTAMYL(9)-; GLUCOSE BLOOD LEVEL;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; ENERGY EXPENDITURE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID DIET; LUNG GAS EXCHANGE; METABOLIC REGULATION; MOUSE; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; DRUG ADMINISTRATION; DRUG EFFECTS; EATING; MOUSE MUTANT;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; DRUG ADMINISTRATION SCHEDULE; EATING; GLUCAGON; HYPOGLYCEMIC AGENTS; MICE; MICE, OBESE; RECEPTORS, GLUCAGON;

EID: 84920473293     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12360     Document Type: Article

References (32)

1. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000; 85: 4053-4059.
2. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 2003; 284: E671-E678.
3. Gromada J, Franklin I, Wollheim CB. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 2007; 28: 84-116.
4. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB. Documentation of hyperglucagonemia through the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987; 64: 106-110.
5. Knop FK, Aaboe K, Vilsbøll T et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab 2012; 14: 500-510.
6. Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 2002; 290: 839-843.
7. Gelling RW, Du XQ, Dichmann DS et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 2003; 100: 1438-1443.
8. Unger RH. Glucagon physiology and pathophysiology in the light of new advances. Diabetologia 1985; 28: 574-578.
9. Johnson DG, Goebel CU, Hruby VJ, Bregman MD, Trivedi D. Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 1982; 215: 1115-1116.
10. Ling A, Hong Y, Gonzalez J et al. Identification of alkylidenehydrazides as glucagon receptor antagonists. J Med Chem 2001; 44: 3141-3149.
11. Madsen P, Ling A, Plewe M et al. Optimization of alkylidenehydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2, 3, 5, 6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. J Med Chem 2002; 45: 5755-5775.
12. Petersen KF, Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 2001; 44: 2018-2024.
13. Qureshi SA, Rios Candelore M, Xie D et al. A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 2004; 53: 3267-3273.
14. Bagger JI, Knop FK, Holst JJ, Vilsbøll T. Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes Obes Metab 2011; 13: 965-971.
15. Russell S. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Int J Clin Pharm 2013; 35: 159-172.
16. Irwin N, Franklin ZJ, O'Harte FPM. desHis1Glu9-glucagon-[mPEG] and desHis1Glu9(Lys30PAL)-glucagon: long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity. Eur J Pharmacol 2013; 709: 43-51.
17. O'Harte FPM, Franklin ZJ, Rafferty EP, Irwin N. Characterisation of structurally modified analogues of glucagon as potential glucagon receptor antagonists. Mol Cell Endocrinol 2013; 381: 26-34.
18. Unson CG, Gurzenda EM, Merrifield RB. Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist. Peptides 1989; 10: 1171-1177.
19. Kerr BD, Irwin N, O'Harte FPM, Bailey CJ, Flatt PR, Gault VA. Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Biochem Pharmacol 2009; 78: 1008-1016.
20. Irwin N, Montgomery IA, O'Harte FPM, Frizelle P, Flatt PR. Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes. Int J Obes (Lond) 2013; 37: 1058-1063.
21. Irwin N, Frizelle P, O'Harte FPM, Flatt PR. (pGlu-Gln)-CCK-8[mPEG]: a novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes. Biochim Biophys Acta 2013d; 1830: 4009-4016.
22. Flatt PR, Bailey CJ. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 1981; 20: 573-577.
23. Gault VA, McClean PL, Cassidy RS, Irwin N. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 2007; 50: 1752-1762.
24. Irwin N, Montgomery IA, Flatt PR. Comparison of the metabolic effects of sustained CCK1 receptor activation alone and in combination with upregulated leptin signalling in high-fat-fed mice. Diabetologia 2013; 56: 1425-1435.
25. Gu W, Yan H, Winters KA et al. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. J Pharmacol Exp Ther 2009; 33: 871-881.
26. Mu J, Jiang G, Brady E et al. Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice. Diabetologia 2011; 54: 2381-2391.
27. Sadry SA, Drucker DJ. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol 2013; 9: 425-433.
28. Liang Y, Osborne MC, Monia BP et al. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 2004; 53: 410-417.
29. Sloop KW, Cao JX, Siesky AM et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 2004; 113: 1571-1581.
30. Bailey CJ, Flatt PR. Animal syndromes resembling type 2 diabetes. In: Pickup JC, Williams G, eds. Textbook of Diabetes. Oxford, UK: Blackwell Science, 2003.
31. Franklin ZJ, O'Harte FPM, Irwin N. Effects of short-term chemical ablation of glucagon signaling by peptide-based glucagon receptor antagonists on insulin secretion and glucose homeostasis in mice. Biol Chem 2014; 395: 433-442.
32. Mayo KE, Miller LJ, Bataille D et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 2003; 55: 167-194.